Related Experiment Videos
[Pregnancy outcome in inflammatory bowel diseases]
R Tennenbaum1, P Marteau, E Elefant
1Services de Gastroentérologie, Hôpital Rothschild, Paris.
Gastroenterologie Clinique Et Biologique
|August 3, 1999
Summary
Women with inflammatory bowel disease (IBD) can have successful pregnancies. Continuing maintenance therapy with 5-aminosalicylates or azathioprine during pregnancy is safe and does not negatively impact outcomes.
Area of Science:
- Gastroenterology
- Obstetrics
- Pharmacology
Context:
- Inflammatory bowel disease (IBD) affects women of childbearing age.
- Pregnancy outcomes in IBD patients require careful consideration regarding disease activity and treatment.
- Previous data on IBD pregnancy outcomes and maintenance therapy have been limited.
Purpose:
- To evaluate pregnancy outcomes in women with inflammatory bowel disease (IBD).
- To assess the relationship between disease activity and maintenance therapy on pregnancy results.
- To determine if stopping maintenance therapy during pregnancy affects pregnancy outcomes.
Summary:
- A postal questionnaire study of 138 women with IBD reported on 144 pregnancies.
- Overall pregnancy outcomes were favorable, with 77% resulting in normal births.
- Preterm birth rates were elevated (11.5%), but normal outcomes were similar for patients continuing or stopping mesalamine, olsalazine, or azathioprine therapy.
Impact:
- Findings suggest that pregnancy outcomes in IBD patients are comparable to the general population, barring increased preterm births.
- Maintenance therapy with 5-aminosalicylates or azathioprine can be safely continued during pregnancy.
- This study provides evidence to guide clinical decisions for managing IBD in pregnant women, potentially improving patient care and reducing treatment-related anxiety.